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INTRODUCTION
Strabismus treatment traditionally includes the correction of re ­
fractive errors, amblyopia treatment, chemical weakening of the 
muscles with botulinum toxin A or a surgical procedure. 
Surgery is a procedure that presents some drawbacks such as 
conjunctival scars and changes in rotational forces which may limit 
ocular motility(1­3). For this reason some attention has been given 
to new substances such as botulinum toxin A and more recently, 
bupivacaine. These medications may promote changes in muscle 
biomechanics not attainable with surgery(4). These changes include 
modulation of muscle force without permanently changing the 
muscle insertion on the eye(5). 
Bupivacaine is an anesthetic drug that has been used in peri­
bulbar and retrobulbar anesthesia for a long time and presents few 
complications(6). Many studies have shown that muscles in which 
bupivacaine was accidentally injected such as in anesthetic blocks for 
cataract surgery, presented a change in ocular alignment with sub­
sequent diplopia(7). Hypertrophy of such muscles after bupivacaine 
injection has been described(8­10). Bupivacaine affects the extraocular 
muscles through selective damage to fibers while preserving cellular 
support structures, nerves and satellite cells. Through growth factors 
released by damaged tissue, the satellite cells proliferate and form 
new muscle fibers repairing the initial damage and causing muscle 
hypertrophy. This hypertrophy increases the stiffness and muscle 
contractility with consequences in ocular alignment. These changes 
are permanent, with alignment stability and muscle hypertrophy 
reported up to 500 days after injection(11).
For the purpose of ocular alignment, bupivacaine should be in­
jected with an aid of a electroneuromiography (EMG) needle under 
topical anesthesia, used to determine the adequate position of the 
needle which would be used to inject the substance intramuscularly, 
in the posterior third of the muscle(4,11,12).
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ABSTRACT
Purpose: To evaluate the change in ocular motility and muscle thickness measured 
with ultrasonography after intramuscular injection of bupivacaine and botulinum 
toxin A.
Methods: Eight patients (five female) were enrolled to measure ocular motility prior 
and 1, 7, 30 and 180 days after one injection of 2 ml of 1.5% bupivacaine and 2.5 U of 
botulinum toxin A in agonist and antagonist muscles, respectively, of eight amblyopic 
eyes. Muscle thickness was measured prior and on days 1, 7 and 30 after injection 
using 10­MHz ultrasonography (eyelid technique). 
Results: Mean change in alignment was 10 prism diopters after 180 days (n=6). 
An average increase of 1.01 mm in muscle thickness was observed after 30 days of 
bupivacaine injection and 0.28 mm increase was observed after botulinum toxin 
A injection, as measured by ultrasonography. Lateral rectus muscles injected with 
bupivacaine had a mean increase of 1.5 mm in muscle thickness. 
Conclusion: In this study, a change in ocular motility was observed after 180 days of 
intramuscular injection of bupivacaine and botulinum toxin in horizontal extraocular 
muscles. Overall, there was an increase of muscle thickness in both botulinum toxinum 
A and bupivacaine injected muscles after 30 days of injection when measured by 
ultrasonography. This change was more pronounced on lateral rectus muscles after 
bupivacaine injection. 
Keywords: Oculomotor muscles; Strabismus/diagnosis; Strabismus/drug therapy; 
Esotropia/drug therapy; Botulinium toxins, type A/administration & dosage; Botuli nium 
toxins, type A/therapeutic use; Bupivacaine/therapeutic use; Bupivacaine/adminis­
tration & dosage; Injections, intramuscular; Ultrasonography
RESUMO
Objetivo: Avaliar a mudança na motilidade ocular e espessura dos músculos medida por 
ultrassonografia após injeção intramuscular de bupivacaína e toxina botulínica tipo A.
Métodos: Oito pacientes (5 mulheres) foram incluidos para avaliar a mudança na mo-
tilidade ocular antes e após 1, 7, 30 e 180 dias da injeção de 2 ml de bupivacaína 1,5% e 
2,5 U de toxina botulínica tipo A nos músculos agonista e antagonista, respectivamente, 
de 8 olhos amblíopes. A espessura muscular foi medida antes após 1, 7, 30 dias da injeção 
através de ultrassonografia ocular 10-MHz (técnica palpebral).
Resultados: A média de mudança no alinhamento ocular foi igual a 10 dioptrias 
pris máticas após 180 dias (n=6). Foi observado um aumento médio de 1,01 mm na 
espessura muscular após 30 dias da injeção de bupivacaína e 0,28 mm após a injeção de 
toxina botulínica A medido pela ultrassonografia. Os músculos reto laterais injetados com 
bupivacaína tiveram um aumento médio de 1,5 mm na sua espessura. 
Conclusão: Neste estudo, observou-se uma mudança no alinhamento ocular após 180 
dias de injeção intramuscular de bupivacaína e toxina botulínica A. Em geral, houve um 
aumento da espessura muscular de ambos os grupos de músculos injetados com toxina 
botulínica A e com bupivacaína após 30 dias da injeção. Essa mudança foi mais pronun-
ciada nos músculos retos laterais após a injeção de bupivacaína.
Descritores: Músculos oculomotores; Estrabismo/diagnostico; Estrabismo/quimioterapia; 
Esotropia/quimioterapia; Toxinas botulínicas tipo A/administração & dosagem; Toxinas 
botulínicas tipo A/uso terapêutico; Bupivacaína/uso terapêutico; Bupivacaína/adminis-
tração & dosagem; Injeções intramusculares; Ultrassonografia
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The present study intends to analyze the effect of bupicavaine 
and botulinum toxin A injections in extraocular muscles with comi­
tant strabismus, evaluating ocular motility and extraocular muscle 
thickness.
METHODS
In this study we prospectively enrolled 8 patients with comitant 
strabismus and either amblyopia or poor vision in one eye. These 
patients underwent injections of 2 ml of 1.5% bupivacaine in the 
lateral rectus (LR) if had esotropia or in the medial rectus (MR) if had 
exotropia and 2.5 U botulinum toxin A in the MR if had esotropia or 
in the LR if had exotropia. The protocol was approved by the Ethics 
Committee ­ Investigational Review Board of the Federal University 
of São Paulo, Brazil.
The criteria for enrollment in the study were: poor vision in one 
eye and comitant strabismus and no previous surgery or botulinum 
toxin A injections. All patients had visual acuity lower than 0.5 in the 
worst eye. Three of them had exotropia and 5 esotropia. 
One ophthalmologist (TSM) used EMG to localize the posterior 
third of the horizontal rectus muscle where the injection of 2 ml of 
1.5% bupivacaine was performed under topical anesthesia (proxi­
metacaine). At least one third of the medication was injected along 
the needle trajectory while the syringe was being withdrawn. The 
injection was performed in the LR in case of esotropia and in the MR 
in case of exotropia. Botulinum toxin A was subsequently administe­
red using Mendonça’s forceps in the contralateral horizontal rectus 
muscle(13). Botulinum toxin A was diluted using 100 U ampoule and 
2 ml of 0.9% saline solution. Subsequently 2.5 U were injected into 
the MR in esotropic patients and into the LR in the exotropic ones. 
All patients underwent ocular ultrasonography (USG) of both eyes 
once before the procedure, and repeated 7 and 30 days after the 
procedure, to determine the thickness of all extraocular muscles. All 
measurements were performed by the same examiner (NA) using a 
10­MHz transducer (Ultrascan, Alcon), and eyelid contact method 
(ultrasound gel was used as a coupling media), with patient’s eye 
aligned in primary position. One eye was examined at the time and 
the patient was asked to fixate on a target with that eye to ensure 
alignment.
Patients underwent a comprehensive ophthalmological exam 
before the procedure. Clinical examination was performed after 1, 7, 
15, 30 days and then monthly until 180 days to determine eye align­
ment, versions and the presence of complications. All the motility 
measurements were performed by the same examiner (LMH) using 
the Krimsky method or the cover/uncover method when the patient 
was able to fixate a target at distance. 
Both examiners for ocular motility exam and ultrasonography 
(LMH and NA) did not have access to medical records with previous 
measurements until all data was collected. 
RESULTS
The eight patients who underwent injection of bupivacaine and 
botulinum Toxin A presented average age of 24.5 years (range 18 to 
53 years), three were male (five, female). 
Five presented the primary diagnosis of esotropia, four of them 
had infantile esotropia and amblyopia, and one had esotropia secon­
dary to macular scar due to toxoplasmosis. The other three patients 
had exotropia. One of which had congenital cataract that had been 
operated and manifest nystagmus, other had poor vision in one eye 
due to a macular scar subsequent to congenital toxoplasmosis and 
the last one had a trauma in childhood with subsequent glaucoma 
and low vision.
Table 1 summarizes the changes in alignment deviation during 
the follow­up. Four patients (2, 3, 6 and 8) developed a transitory 
vertical deviation due to the effect of the botulinum toxin A, which 
was recovered by day 180. Ptosis of 1 mm was present in patients 
1 (Figure 4), 5, 7 and 8 at the 7th, 15th and 30th days of follow­up visit. 
Patient 2 presented a 2 mm ptosis and patient 4, 4 mm ptosis, presen­
ted at the 7th, 15th, 30th and 60th days of follow­up visit. The overall mean 
change in deviation was 10 prism diopters at the 180th day visit. Patients 
4 (Figure 5) and 8 had an increase in deviation on day 1. All patients had 
the smallest angle of deviation at days 15 and 30. Patients 2, 3 and 4 
had a higher deviation on the 60th day than the previous visit, with a 
decrease on deviation the 180th day. Patients 5 and 6 were excluded 
due to lack of follow­up data at the 60th and 180th days visit.
Figure 1 and table 2 show the thickness of the muscle injected 
with botulinum toxin type A measured by USG before the injection 
and after 7 and 30 days of the procedure. Figure 2 and table 3 show 
the thickness of the muscle injected with bupivacaine also measured 
by USG before the injection and after 7 and 30 days. Patient 5 under­
took the USG exam 60 days after injection instead of 30 because of a 
not related clinical intervention. Figure 3 shows the muscle thickness 
before and after injection in each group of muscles ­ LR and MR.  
Ultrasonography showed an average increase in thickness of the 
muscle injected with Bupivacaine on the 7th day of 0.43 mm. The 
mean increase of muscle thickness after 30 days injection of bupiva­
caine was equal of 1.01 mm, and after botulinum toxin A injection 
was equal of 0.28 mm. When comparing before and after injection, 
an increase in thickness of the LR injected with botulinum toxin A 
(0.6 mm) and with bupivacaine (1.5 mm) was observed in thickness 
for each group of muscles. There was no increase in thickness of the 
MR injected with bupivacaine, and a small increase in the botulinum 
toxin A MR injected group (0.1 mm).
One patient (patient 5) presented a retrobulbar hemorrhage du­
ring bupivacaine injection in the MR. The complication was treated 
using compressive bandage of the eye with adequate control of IOP 
and proptosis. After 60 days the patient showed no change in visual 
acuity and no optic disc abnormality at fundoscopy, but a decrease 
in the pupillary response with medium mydriasis. 
Table 1. Change in deviation in the study population presenting comitant strabismus before and after injection of bupivacaine and botulinum 
toxin in prism diopters (PD) 
Patient
Initial deviation
(PD)
Day  1
(PD)
Day  7
(PD)
Day  15
(PD)
Day  30
(PD)
Day  60
(PD)
Day 180
(PD)
Variation
(PD)
1 ET60HTE10 ET50HTE10 ET45HTE10 ET30HTE8 ET25HTE8 ET45HTE10 ET45HTE8 15
2 ET20 ET20HTE4 ET20 ET15HTE2 ET10 ET20 ET15 5
3 XT45 XT45 XT50HTD6 XT30 XT30 XT40 XT30 15
4 ET50 ET56 ET50 HTE4 HTE6 ET35HTE6 ET30 20
5 XT62 XT60 XT50 XT45 ­ XT56 ­ ­
6 ET20 ET20 ET15 ET4HTE8 ET15HTE2 ­ ­ ­
7 XT45HoTD10 XT40 HoTD10 XT25HoTD8 XT20HoTD10 XT30HoTD10 XT30 HoTD10 XT40 HoTD10 5
8 ET20 ET25 ET12 ET10HTE2 ET20 ET20 ET20 0
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DISCUSSION
In this study we chose to inject bupivacaine and botulinum toxin 
A only once in patients who had not been operated on before. This 
protocol was performed to evaluate the effect of one injection of a 
specific concentration and volume of bupivacaine (2 ml in 1.5%) and 
botulinum toxin A (2.5 U). In a previous study some patients had been 
operated on before the procedure and different dosages of bupiva­
caine and botulinum toxin A were administered(4).
Scott et al., have demonstrated that the alignment achieved with 
the injection of bupivacaine in the agonist muscle and botulinum 
toxin A in the antagonist muscle was 19.7 prism diopters in comitant 
strabismus(4). Another study demonstrated changes of 6.1 prism 
dio pters in esotropias treated only with bupivacaine in the lateral 
rec tus of the affected eye(11). We found an average correction of 10 
prism diopters over 180 days. It is believed that this correction was 
due not only to the botulinum toxin A, since it was applied in low 
doses, though it allows a temporary paresis of the muscle while the 
antagonist muscle is being reloaded after bupivacaine application(4). 
We observed that patients 1, 3 and 4, who presented greater 
change in alignment, showed paresis of the two horizontal muscles 
(medial and lateral rectus) injected with medications during the re­
generation period of the muscle. The same observation was stated in 
a previous study(14). All patients had the smallest deviation between 
15 and 30 days after injection which is consistent with the peak of 
action of botulinum toxin A.
All patients from this series had low visual acuity in one eye, 0.5 
logMAR or worse, thus Krimsky test was used to determine the angle 
of strabismus in most of them, due to their unsteady fixation. This 
method has already been described as variable even for experien­
Figure 1. Change in muscle thickness in millimeters (mm) measured by ocular ultraso-
nography after botulinum toxin A injection in comitant strabismus.
Figure 2. Change in muscle thickness in milimeters (mm) measured with ocular ultra-
sonography after bupivacaine injection.
Figure 3. Muscle thickness of medial rectus (MR) and lateral rectus (LR) before and after 
injection of botulinum toxin A and bupivacaine in millimeter (mm)
ced examiners(15), reason that could explain the variability on some 
measurements, such as patients 4 and 8 on the 1st day, and patients 
2, 3, 4 on the 60th day. 
It is being advocated that intramuscular injection of bupivacaine 
induces a degeneration of muscle fibers that will end up activating 
satellite cells and regeneration of new muscle fibers between the 
10th and 20th days after injection, continuing to build a muscle with 
grea ter contractility and size at least until the 180th day (11). Few 
studies report the clinical effect of bupivacaine to treat strabismus, 
thus it is still unclear the exact onset of its clinical effect and peak of 
action. Scott et al., reported an onset of clinical effect after 16 days of 
bupivacaine intramuscular injection(11). Botulinum toxin A has a peak 
of action between 1 to 2 weeks after injection and will last until an 
average of 3 months(16). That difference in time of action could explain 
the variability on some measurements, such as for patients 2, 3, 4 on 
the 60­day visit. 
We observed greater technical difficulty in injecting bupivacaine 
into the medial rectus vs. the lateral rectus. This might have influen­
ced the result in patient 5, who presented a complication of the pro­
cedure ­ retrobulbar hemorrhage; that resulted in an abnormal pupil 
but no deterioration in vision. Thus far, considering complications 
arising after the application of intramuscular bupivacaine, a previous 
study reported a case of orbital inflammation, which spontaneously 
resolved(4). 
As complications related to the intramuscular injection of botu­
linum toxin A, we observed ptosis of the upper eyelid and vertical 
deviation. Ptosis was present in 75% of the patients and fully reco­
vered by 180 days after injection, compared to previous studies that 
report up to 53% of the patients(14). Vertical deviation was described 
in previous studies with a frequency of 2 to 16%(14) and the time to 
recovery around 6 weeks. In our series, vertical deviation occurred in 
62.5% of the patients, all of them recovered by 180 days. 
In the present series, there was an increase in muscle thickness for 
both groups, injected with botulinum toxin A and bupivacaine, but 
the second group presented a greater amount of response. Previous 
studies showed increase in muscle volume after 33 days(11) and up 
to 350 days(4) of bupivacaine injection using the imaging method 
magnetic resonance imaging (MRI). Although USG and MRI are two 
different imaging methods, both showed increased muscle thickness 
after the injection of bupivacaine. Both methods had been used to 
determine extraocular muscle thickness. Ultrasonography is conside­
red a more accessible and cost­effective imaging method to evaluate 
extraocular muscle thickness, with less contraindication, allowing 
considerations about internal reflectivity(17). In a previous report using 
USG and MRI techniques to determine extraocular muscle thickness, 
the average thickness for each rectus muscle was found to be similar, 
with reference that the ultrasound related measurements should be 
Bupivacaine and botulinum toxin to treat comitant strabismus
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interpreted cautiously(17). Patients 4 and 8 presented a decrease in 
muscle thickness after botulinum toxin A injection, and patient 3 
had a decrease in muscle thickness after bupivacaine injection when 
measured by USG. These findings could be explained due to the 
intrinsic variability of the ultrasonographic method for determining 
muscle thickness. 
Figure 4. (patient 1): First row: Before injection of Bupivacaine and Botulinum toxin ET50. Second row: 15th day 
of follow-up HTE4. Third row: 30th day of follow-up, HTE6. Fourth row: 60th day of follow-up,ET35HTE6. Fifth row: 
180th day of follow-up, ET30.
Figure 5. (patient 4): First row: Before injection of Bupivacaine and Botulinum toxin ET60HTE10. Second row: 15th 
day of follow-up ET30HTE8. Third row: 30th day of follow-up, ET25HTE8. Fourth row: 60th day of follow-up,ET45HTE10. 
Fifth row: 180th day of follow-up, ET45HTE8.
When compared with previous normal values for muscle thick­
ness in patients without strabismus, measured by a similar method 
(10 MHz ultrasound, Mentor TM Advent Ultrasonic diagnostic ima ­
ging system), the present series presented a higher average of thick­
ness both for medial rectus (3.9 mm vs 3.5 mm) and for lateral rectus 
before injection (3.6 mm vs. 3 mm)(18). This finding could be explained 
Hopker LM, et al.
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Table 2. Variation in muscle thickness determined by 
ocular ultrasonography after botulinum toxin injection in 
comitant strabismus in milimeters (mm)
Muscle thickness measurement after  
botulinum toxin injection (mm)
Patient Initial Day 5 Day 30 Variation
1 3.4 3.8 4.5 ­1.1
2 4.0 3.9 4.0 ­0.0
3 4.4 4.4 4.4 ­0.0
4 3.5 3.3 3.0 ­0.5
7 3.0 3.4 4.2 ­1.2
8 4.1 4.4 4.0 ­0.1
Table 3. Variation in muscle thickness determined by ocular 
ultrasonography after bupivacaine injection in comitant 
strabismus in milimeters (mm)
Muscle thickness measurement after  
bupicavaine injection (mm)
Patient Initial Day 7 Day 30 Variation
1 3.4 3.4 5.5 ­2.1
2 3.9 4.1 5.7 ­1.8
3 4.2 4.8 3.4 ­0.8
4 3.0 3.7 5.1 ­2.1
7 3.7 5.0 4.5 ­0.8
8 3.8 3.6 3.9 ­0.1
by a muscular contracture and/or by the abnormal position of the eye 
due to comitant strabismus. When compared the increase in muscle 
thickness of LR with MR after injections, we observed that both LR 
injected with botulinum toxin A and bupivacaine had an increase 
in thickness, while MR muscles only showed a small increase when 
injected with botulinum toxin A. No change was observed after 
bupivacaine injection in MR. Injecting the posterior third of the MR 
was technically more difficult than injecting into the LR. It is possible 
that the bupivacaine was not accurately placed in the MR, which can 
explain the difference in measurements comparing the two groups 
of muscles. The importance of the injection site has previously been 
emphasized(4).
Ultrasonography is considered a dynamic exam, and even when 
performed by the same trained examiner may produce variable 
results in extraocular muscle thickness especially in patients with 
strabismus. This could be possibly influenced by the position of the 
eye and the amount of contracture of the muscle. To our knowledge, 
no previous studies determine normal values for extraocular muscle 
thickness in adult patients with strabismus.
Best effects in comitant strabismus treatment are achieved with 
bupivacaine in concentrations of 3.0%, 2.0% and 1.5% and a volume of 
between 2 and 4 ml injected into the target muscle(4). In this study, the 
volume of 2 ml and the concentration of 1.5% bupivacaine were used 
to assess the resulting average correction for this given volume and 
concentration. We believe that future studies should vary concentration 
and volume to observe differences in the changes in ocular alignment.
CONCLUSION
To date, few reports addressed the treatment of strabismus with 
bupivacaine and botulinum toxin A and the measurement of muscle 
thickness after its injection. In this study we observed a mean change 
of 10 diopters of ocular alignment after 180 days of injection. Ove­
rall, there was an increase of muscle thickness after both botulinum 
toxinum A and bupivacaine injections after 30 days. This change 
was more pronounced on lateral rectus muscles after bupivacaine 
injection. This study demonstrates that the injection of bupicavaine 
associated with botulinum toxin A in extraocular muscles may be 
useful for the treatment of small to moderate horizontal strabismus, 
as an option for the surgical treatment.
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